CBT Pharmaceuticals’ PD-L1 Antibody Shows Promising Anti-Tumor Activity in Preclinical Studies

CBT Pharmaceuticals’ PD-L1 Antibody Shows Promising Anti-Tumor Activity in Preclinical Studies

CBT Pharmaceuticals‘ anti-PD-L1 antibody CBT-502 has shown promising immune activation and inhibition of tumor growth in preclinical models of cancer, according to new preclinical data.

The data were presented in a poster titled, “CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models,” at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.

Studies showed that this new drug candidate stimulates the production of the cytokines interleukin-2 (IL-2) and interferon gamma (IFN-gamma), leading to suppression of tumor growth in models of colon cancer and melanoma. It produced these results with a similar effectiveness as Tecentriq (atezolizumab), another PD-L1 inhibitor.

“The in-vitro characteristics and in-vivo efficacy studies showing linear pharmacokinetics suggest that CBT-502 may provide benefit in a variety of tumor types,” Sanjeev Redkar, PhD, president and chief executive officer at CBT, said in a press release.

Redkar added that compared to other PD-L1 blockers on the market today, CBT-502’s molecular composition “may offer a point of differentiation in the clinical setting.”

Several cancer cell types present high levels of PD-1, the receptor of PD-L1. The binding of PD-L1 to PD-1 inhibits activated T-cells (a type of immune cell), which are crucial in killing tumor cells. Therefore, the therapeutic blocking of PD-L1 reduces tumor growth by stimulating the activity of T-cells.

The research showed that CBT-502 efficiently and specifically inhibited the binding of PD-L1. Furthermore, the researchers observed an increased release of IL-2 and IFN-gamma, which proved that CBT-502 augmented human T-cell activation.

Importantly, in mouse models of human melanoma and colon adenocarcinoma, CBT-502 significantly inhibited tumor growth in a dose-dependent manner. This effect was comparable to Genentech’s Tecentriq.

Additionally, pharmacology and toxicology data of CBT-502 showed effective activity with a wide margin of safety.

“These studies support our commitment to advancing the clinical development of CBT-502 as an immuno-oncology therapy for a variety of cancers,” said Gavin Choy, executive vice president and chief operating officer at CBT.

Investigational new drug studies, which facilitate clinical research, “will commence in 2018 and a phase 1/2 combination study will be initiated in the second half of 2018 in Australia,” he added. 

CBT-502 is being developed by Chia Tai Tianqing (CTTQ) Pharmaceutical Group for commercialization in China. CBT has marketing rights for the rest of the world.

José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
×
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
Latest Posts
  • Keytruda
  • NKTR-214
  • Tecentriq
  • THOR-707